In FR Doc. 97–947, beginning on page 2218 in the **Federal Register** of January 15, 1997, the following corrections are made in § 310.518 *Drug products containing iron or iron salts*:

§ 310.518 [Corrected]

1. On page 2250, in the second column, in paragraph (b)(2), beginning in the fourth line, the phrase ''the provisions of § 111.50(a) of this chapter'' is corrected to read ''the provisions of paragraph (a) of this section''.

2. On page 2250, in the third column, in paragraph (c)(5), in the second line, the phrase ''paragraph (b)(1) of this section'' is corrected to read ''paragraph (c)(1) of this section''.

Dated: March 25, 1997.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 97–7970 Filed 3–28–97; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Parts 520 and 558

Animal Drugs, Feeds, and Related Products; Ronnel; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to remove that portion of the regulations reflecting approval of new animal drug applications (NADA's) held by Moorman Manufacturing Co. and Pitman-Moore, Inc., that provide for the use of ronnel oral dosage forms and ronnel Type A medicated article. The approval of these NADA's were previously withdrawn. This action is necessary to ensure the accuracy and consistency of the regulations.

EFFECTIVE DATE: March 31, 1997.

FOR FURTHER INFORMATION CONTACT: David L. Gordon, Center for Veterinary Medicine (HFV–238), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1737.

SUPPLEMENTARY INFORMATION: FDA has discovered that certain errors have been incorporated into the agency's codified regulations on animal drugs. The errors in the regulations addressed in this document follow.

In a notice published in the **Federal Register** of July 19, 1989 (54 FR 30268), the agency announced that Pitman-Moore, Inc., had requested that FDA withdraw NADA's 12–360 and 12–361. In a final rule published in that same issue of the **Federal Register** (54 FR 30205), the agency inadvertently omitted an amendment to the regulations to remove § 520.2080 (21 CFR 520.2080).

In a notice published in the **Federal Register** of June 18, 1990 (55 FR 24646), the agency announced that Moorman Manufacturing Co. had requested that FDA withdraw NADA 13–450. In a final rule published in that same issue of the **Federal Register** (55 FR 24556), the agency inadvertently omitted an amendment to the regulations to remove § 558.525 (21 CFR 558.525).

At this time, the agency is correcting these errors. Accordingly, §§ 520.2080 and 558.525 are removed because the sections no longer represent approved products.

List of Subjects

21 CFR Part 520

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and 558 are amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 520.2080 [Removed]

2. Section 520.2080 *Ronnel oral dosage forms* is removed.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

3. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.525 [Removed]

4. Section 558.525 *Ronnel* is removed.

Dated: March 4, 1997.

Linda Tollefson,

Director, Office of Surveillance and Compliance, Center for Veterinary Medicine.

[FR Doc. 97–8048 Filed 3–28–97; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 558

New Animal Drugs For Use In Animal Feeds; Tylosin; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a final rule that appeared in the **Federal Register** of December 24, 1996 (61 FR 67713). The document amended the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Elanco Animal Health, Division of Eli Lilly and Co. The approved use level of tylosin Type C medicated swine feed was inadvertently omitted from the document. The document also contained certain editorial errors. This document corrects those errors.

EFFECTIVE DATE: December 24, 1996.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV–133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1644.

In FR Doc. 96–32549, appearing on page 67713 in the **Federal Register** of Tuesday, December 24, 1996, the following correction is made:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.625 [Corrected]

2. On page 67713, in the second column, § 558.625 is amended by revising paragraph (f)(1)(vi)(*e*) to read as follows:

§ 558.625 Tylosin.

* * * * *

(f) * * *

(1) * * *

(vi) * * *

(*e*) *Amount per ton.* Tylosin 100 grams.

(*1*) *Indications for use.* Prevention and/or control of porcine proliferative enteropathies (ileitis) associated with *Lawsonia intracellularis.*

(*2*) *Limitations.* As tylosin phosphate, administer for 21 days.

Dated: February 6, 1997.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 97–8049 Filed 3–28–97; 8:45 am]

BILLING CODE 4160–01–F